|
|
范文
[1] Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J,
Leverenz JB, Del Tredici K, Wszolek ZK and Litvan I. Neuropathological assessment of
Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009; 8: 1150-1157.
[2] Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN and Braak E. Staging of
brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-
211.
[3] Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R and Goedert M. Alphasynuclein in Lewy bodies. Nature 1997; 388: 839-840.
[4] Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H,
Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A,
Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI and
Nussbaum RL. Mutation in the alpha-synuclein gene identified in families with
Parkinson's disease. Science 1997; 276: 2045-2047.
[5] Lesage S, Anheim M, Letournel F, Bousset L, Honore A, Rozas N, Pieri L, Madiona K,
Durr A, Melki R, Verny C and Brice A. G51D alpha-synuclein mutation causes a novel
parkinsonian-pyramidal syndrome. Ann Neurol 2013; 73: 459-471.
[6] Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, Sherman H, Yu I, Shah B, Weir D,
Thompson C, Szu-Tu C, Trinh J, Aasly JO, Rajput A, Rajput AH, Jon Stoessl A and
Farrer MJ. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's
disease. Mov Disord 2013; 28: 811-813.
[7] Hoffman-Zacharska D, Koziorowski D, Ross OA, Milewski M, Poznanski J, Jurek M,
Wszolek ZK, Soto-Ortolaza A, Slawek J, Janik P, Jamrozik Z, Potulska-Chromik A,
Jasinska-Myga B, Opala G, Krygowska-Wajs A, Czyzewski K, Dickson DW, Bal J and
Friedman A. Novel A18T and pA29S substitutions in alpha-synuclein may be associated
with sporadic Parkinson's disease. Parkinsonism Relat Disord 2013; published online 05
August 2013:
[8] Ishizawa T, Mattila P, Davies P, Wang D and Dickson DW. Colocalization of tau and
alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 2003; 62: 389-397.
[9] Fujishiro H, Tsuboi Y, Lin WL, Uchikado H and Dickson DW. Co-localization of tau and
alpha-synuclein in the olfactory bulb in Alzheimer's disease with amygdala Lewy bodies.
Acta Neuropathol 2008; 116: 17-24.
[10] Duda JE, Giasson BI, Mabon ME, Miller DC, Golbe LI, Lee VM and Trojanowski JQ.
Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta
Neuropathol 2002; 104: 7-11.
[11] Markopoulou K, Dickson DW, McComb RD, Wszolek ZK, Katechalidou L, Avery L,
Stansbury MS and Chase BA. Clinical, neuropathological and genotypic variability in
SNCA A53T familial Parkinson's disease. Variability in familial Parkinson's disease. Acta
Neuropathol 2008; 116: 25-35.
[12] Braak H and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta
Neuropathol 1991; 82: 239-259.
[13] Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes
JP, van Belle G and Berg L. The Consortium to Establish a Registry for Alzheimer's
Disease (CERAD). Part II. Standardization of the neuropathologic assessment of
Alzheimer's disease. Neurology 1991; 41: 479-486.
[14] Beach TG, White CL, Hamilton RL, Duda JE, Iwatsubo T, Dickson DW, Leverenz JB,
Roncaroli F, Buttini M, Hladik CL, Sue LI, Noorigian JV and Adler CH. Evaluation of
alpha-synuclein immunohistochemical methods used by invited experts. Acta
Neuropathol 2008; 116: 277-288.
|
|
发表于 2021-2-18 21:11:17
发表于 2021-2-18 23:46:29
